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Summary
Blood transfusion and iron chelation currently represents a supportive therapy
to manage anaemia, vasculopathy and vaso-occlusion crises in Sickle-Cell-Disease.
Here we describe the first 5-years long-term randomized clinical trial
comparing Deferiprone versus Deferoxamine in patients with Sickle-Cell-Disease.
The results of this study show that Deferiprone has the same effectiveness as
Deferoxamine in decreasing body iron burden, measured as repeated measurement of
serum ferritin concentrations on the same patient over 5-years and analyzed
according to the linear mixed-effects model (LMM) (p=0.822).
Both chelators are able to decrease, significantly, serum ferritin concentrations,
during 5-years, without any effect on safety (p=0.005). Moreover, although the basal
serum ferritin levels were higher in transfused compared with non transfused group
(p=0.031), the changes over time in serum ferritin levels was not statistically
significant different between transfused and non-transfused cohort of patients
(p=0.389).
Kaplan-Meier curve, during 5-years study, suggests that Deferiprone does not
alter survival in comparison with Deferoxamine (p=0.38).
In conclusion, long-term iron chelation therapy with Deferiprone was
associated with efficacy and safety similar to that of Deferoxamine. Therefore, in
patients with Sickle-Cell-Disease, Deferiprone may represent an effective long-term
treatment option.

Key points: Chelation in Sickle-Cell-Disease, Effectivenes of Deferiprone in SickleCell-Disease, DFP versus DFO in Sickle-Cell-Disease
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Introduction
Blood transfusion currently represents a supportive therapy to manage
anaemia, vasculopathy and sickle vaso-occlusion. In adults, aggressive transfusion to
treat and improve organ dysfunction is used [1,2] more frequently and chronic
transfusion therapy significantly reduces the risk of primary and secondary stroke in
paediatric patients with Sickle- Cell-Disease (SCD) [3,4].Therefore, transfusional
iron overload has been associated with morbidity and mortality in SCD [5].
Patients with SCD show differences in iron metabolism and trafficking
compared with other haemoglobinopathies. Particularly, the effects of inflammatory
cytokines in SCD may lead to increased iron levels in reticuloendothelial,
macrophage and renal cells, resulting in different tissues and organs being affected by
iron overload in SCD compared with β thalassaemia [6]. Moreover, urinary loss of
iron from intravascular haemolysis and lower levels of Non-Transferrin-Bound-Iron
(NTBI) due to inflammation may contribute to the different patterns of iron overload
[7].
Regularly transfused patients with SCD still have increased liver iron
concentration (LIC), which has been shown to correlate significantly with the volume
and duration of transfusions. Increased LIC is also associated with liver fibrosis [810].
As a result, guidelines currently recommend initiating iron chelation therapy in
patients with SCD once LIC increases to > 7 mg Fe/g dry weight, if steady state
serum ferritin levels are >1000 ng/l, or if patients have received cumulative
transfusions of 120 cc packed red blood cells/kg [1] or at least 20 units of blood
transfusions [11]. Safety and effectiveness of iron chelation in SCD has been
reported only in a large prospective clinical trial of Deferasirox (DFX) where patients
with SCD completing a 1-year, Phase II, randomized, Deferoxamine (DFO)controlled study [12] entered a 4-year extension, continuing to receive DFX, or
switching from DFO to DFX [13].
However, long-term safety and effectiveness findings in SCD have not been
reported from randomized clinical trials comparing oral chelation with DFO.
Moreover, no data on long-term Deferiprone (DFP) safety and efficacy of DFP
treatment in SCD has been reported.
Therefore, we conducted a 5-year-trial of DFP versus DFO in Italian
population with SCD to assess the impact of these two chelators on serum ferritin
concentrations, safety, costs and survival analysis in patients with SCD.
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Materials and methods
Design
The trial was a 5-year multicenter randomized open-label trial with blinded
data management and data analyses, to assess whether either treatment was superior
to the other.
The trial was performed on behalf of the Italian Society for the Study of
Thalassaemia and Haemoglobinopathies (SoSTE) (http://www.soste.org).
The investigators initiated, carried out, and controlled the trial, which was
conducted without the influence of the sponsor [14]. Other 5-years of follow-up after
the end of the trial was planned. The trial was registered at
http://www.clinicaltrials.gov, Identifier NCT00733811.
Patients
Consecutive SCD patients observed at 9 centers in Italy between January 2001
and May 2011 were eligible for the trial if they had a serum ferritin concentration
between 800 and 3000 ng/ml and were over 13 years of age.
Parents gave informed consent for patients between 13 and 18 years of age.
The data were collected at the coordinating centre (A.O.V. Cervello, U.O.C. di
Ematologia II, Palermo, Italy).
The diagnosis of SCD was based on accepted clinical and molecular criteria
[15]. The exclusion criteria were (i) known intolerance to one of the trial treatments,
(ii) platelet count <100,000/µl or leucocyte count <3000/µl (iii) severe liver damage
as indicated by Child-Plugh C grade classification, (iv) sepsis at entry and (v) overt
heart failure. Eligibility and exclusion criteria were checked at each participating
centre, where the patients were also seen throughout the entire follow-up period.
If the patients were treated with subcutaneous (sc) administration of DFO (3050 mg/kg per day, 8–12 h for 5 d a week) before inclusion in the trial, wash-out from
DFO for 1 week was performed before randomization after verifying inclusion and
exclusion criteria. The same timing was used if the patient was on DFX and
randomized to DFO. Figure 1 shows the trial profile.

Randomization
The randomization sequence was based on a computer randomized list in
permuted blocks of 10 with a 1:1 ratio, generated at the Department of Scienze
Economiche, Aziendali e Statistiche of the University of Palermo, Italy. To ensure
allocation concealment, treatment was assigned by telephone contact from the
coordinating center. The sequence was concealed until interventions were assigned.
Randomization was performed for each consecutive patient after verification of
the exclusion criteria. Treatment was started within the following 24 h. Patients
4

visited the clinic monthly where clinical and predefined data forms were collected.
The data were regularly forwarded to the coordinating center, where a complete
database for all included patients was established.
Interventions
Trial interventions were DFP (Apotex; Toronto, ON, Canada) at 75 mg/kg/day,
divided into three oral daily doses, for 7 d/week versus DFO (BiofuturaPharma,
Pomezia, Italy) by sc infusion (8–10 h) at 50 mg/kg per day for 5 d/week A doubleblinded design was not considered to be possible because of the sc administration of
DFO. The planned duration of treatment was 5 years.
During this period, treatment was only interrupted at the discretion of the
investigators if needed for intercurrent illness or adverse events (AEs). Count blood
cell was performed weekly for monitoring, according to the manufacturing
recommendations for DFP.
Dose modifications were allowed for safety reasons. Criteria for dosage
reduction treatment to DFP 50 mg/kg per day were arthralgia and nausea not
controlled by symptomatic therapy and for reduction treatment to DFO 30 mg/kg per
day were local reactions at the site of infusion. Both treatments were reduced if the
ferritin levels on two consecutive determinations were less than 400 ng/ml. Treatment
was restarted when ferritin levels were greater than 700 ng/ml on at least two
determinations.
Treatment failure was defined as an increase of serum ferritin levels more than
1000ng /ml from baseline, confirmed in at least two consecutive determinations.
Patients who failed were switched to the alternative treatment and followed until the
end of the study.
All outcome assessments were coded by physicians blinded to the trial
treatment. Drug administration was recorded on the case report form. Assessments
for safety and efficacy were performed at monthly planned follow-up visits.
Compliance was assessed by counting the pills in each returned bag of DFP
and by assessing the number of infusions of DFO registered on the electronic pump
(CronoTM, Gene S.r.l., Italy).
Primary and secondary outcomes
The primary end point of treatment efficacy was the change from the baseline
value in serum ferritin levels during the 5 years. Secondary endpoints were safety and
survival analysis at 5-years.

Follow-up after the trial
Other 5-years of follow-up, after the end of the trial , was planned to collect
5

data on survival about this cohort of patients. During this period patients were
allowed to change chelation. Data about causes and chelation treatment at death were
collected during this period.
Sample size estimation
Sample size estimation for the two treated groups was performed taking into
account repeated measures as discussed in Rochon [16]. For our study, the
recommended number of subjects was between 40 and 100.
A minimum number of patients required in each treatment group was
calculated assuming equal allocation, under the hypothesis of equality between the
two treatment groups at every point during the course of the trial for the
autoregressive correlation structure, for a two-sided test at α=0.05, β=0.80, ∆=0.41
(standardized effect), ρ=0.60, and number of follow-up measurements T = 5.
Costs
The costs of chelation treatments were calculated for the overall period of
observation based on cost for 1-day treatment per each person multiplied by the
person-years of treatment.
Periods of reduced dosage were also considered for the cost analysis. The cost
data were obtained by the Italian Ministry of Health.
Ethics
The study was conducted according to the Declaration of Helsinki
(http://www.wma.net/e/policy/b3.html) and was approved by the local Institutional
Review Board (IRB) of each participant center.
The patients (or the parents of minors) gave their written informed consent to
participate in the trial. Trial was conducted according to GMP and the EU clinical
trials directive.
Statistical methods
All descriptive and inferential statistical analyses were performed under code
of the Department of Scienze Economiche, Aziendali e Statistiche from the
University of Palermo, by a statistician (A. V.) blinded to the trial interventions,
using STATA 12.0 software (StataCorp, College Station, TX, USA).
Statistical significance is declared when the p-value is less than 0.05. All
statistical tests are two-sided. For the purpose of statistical analyses, missing scores
were not included. Thus, observed case analyses have been employed for efficacy
determinations.
Baseline descriptive statistics were presented for each variable. Specifically,
for categorical variables, the number and the percent of each category within a
6

parameter were calculated for non-missing data, and difference in the two treatment
arms was compared using a Fisher’s exact test. For continuous variables, the mean,
standard deviation values were derived, and the comparisons between the baseline
mean difference in the two intervention groups were based on a t-test.
Data on serum ferritin levels consists of repeated measurement on the same
patient over time. For the purpose of the study a linear mixed-effects model (LMM)
was used [17]. A mixed model analysis in such a study does not require complete
data from all subjects. This results in more appropriate estimates of the effect of
treatment and their standard errors. The analysis was based on a LMM where the
patient effect (given by the intercept terms for each patient) was regarded as random
effect, while the treatment effect (treat), the time effect (time), the treatment-by-time
interaction effect (treat×time), and the total transfutions in ml (tot TX) were regarded
as fixed effects. In developing this model, the fact that measurements taken on the
same patient may not be independent of one another, was taken into account. In this
context, an autoregressive correlation of order 1, AR (1) structure, was considered to
model correlation within repeated observations. The same analysis (LMM) was
applied to look at possible statistical significant difference between transfused and
non-transfused SCD group.
The Kaplan–Meier method was used to estimate survival probability for the
two treated groups of the randomized patients. The survival curves were compared
per treatment group using the log-rank test. Survival analysis was performed from
January 30, 2001 to January 30, 2006. Data about causes and chelation at death, after
5-years from the end of the study was collected and reported.
Results
Participant recruitment and flow
Consecutive SCD patients (n = 94) between January 30,2001 and January 30,
2006 were considered to be eligible for the trial (Fig 1).
Four patients did not meet inclusion criteria and 30 patients declined to
participate (Fig 1). The remaining 60 patients were included; 30 and 30 respectively,
were randomly allocated to DFP versus DFO treatment (Fig 1). No patients were lost
to follow-up.
Baseline data
Hematological and clinical findings at enrolment are shown in Table 1. No
differences were observed at baseline between the two randomized groups (Table 1).
Particularly, the degree of iron overload, expressed by serum ferritin at
baseline, and the amount of blood transfusions requirement, were similar in the two
groups (Table 1). Therefore, these findings suggest that severity of body iron burden
was similar between the two groups (Table 1).
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Serum ferritin concentrations
Table 2 shows baseline and follow-up mean serum ferritin values during the 5year treatment.
Table 3 shows results of statistical modelling process to evaluate efficacy of
DFP versus DFO treatment based on repeated measures of serum ferritin values
during the study period.
Figure 2 shows the fitted effects of serum ferritin levels in the two treatment
groups. Cases of patients with serum ferritin levels < 400 ng/ml were detected. The
incidence of patients with serum ferritin levels < 400 ng/ml was higher in the DFP
group (11 patients, 36.6%) in comparison with the DFO group (1 patient, 3.3%). This
difference was statistically significant (p-value=0.002).
Transfused and non-transfused patients with SCD showed significant changing
over time in serum ferritin levels (p=0.029) (Table 4). Moreover, although the basal
serum ferritin levels were higher in transfused compared with non transfused group
(p=0.031), the changes over time in serum ferritin levels was not statistically
significant different between the two cohorts of patients (p=0.389) (Table 4).

Adverse events and treatment failure
Table 5 reports the main side effects in the two groups. The overall period of
observation was 192 person-years for DFP patients compared with 196 person- years
for DFO patients.
Sixteen subjects in the DFP and 13 in the DFO group withdrew definitely from
the trial (Table 5). The mean time for definitive withdrawal was 77.7±93.8 (days) in
the DFP group versus 191.4±153 (days) in the DFO group respectively. There was no
statistically significant difference in temporary and definitive discontinuation of
treatment between the groups (p=0.764) during the overall period of observation.
Dosage decrease was necessary in 2 of DFP patients versus 1 of DFO patients.
There was only one case of treatment failure in the DFO group and no case in DFP
group.
No patients with agranulocytosis were reported in the DFP-treated group
(Table 5). Nine and seven patients received hydroxycarbamide during DFP and DFO
chelation treatment, respectively.
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Survival analysis during the trial
Survival analysis was extended for the 5-years of the trial (Fig. 3). The KaplanMeier survival probability curves of the two treatment groups are reported on Fig. 3.
The intention-to treat analysis did not show any statistically significant difference
between the two groups (Fig. 3; p=0.38). The causes of death for single chelation
treatment are reported on Table 6.

Follow-up after the trial
Data about causes and chelation treatment at death, after 5-years from the end
of the study, are reported on Table 7. Kaplan-Meier survival probability at 10-years
(graph not shown) did not show any statistically significant difference between the
two groups (p=0.88).

Compliance and costs
In the DFP group, compliance was 89%, while with DFO was 75%. The
calculated mean ± SD cost was 4581 ± 1598 Euros per person-year (range 983 –
6209) for DFP treatment versus 4966 ± 2117 Euro per person-year (range 488 –
7352) for DFO treatment. This difference was not statistically significant (p= 0.43).

Discussion
The increased life expectancy of patients with SCD has led to a need for longterm iron chelation therapy to prevent the onset of complications associated with iron
overload, but long-term iron chelation data in SCD are currently limited to DFX.
The current study is the only study to date to assess the long-term efficacy and
safety of DFP, during a long-term randomized clinical trial in patients with SCD. The
results of this study show that DFP has the same effectiveness as DFO in decreasing
serum ferritin concentration, without increasing adverse events or costs.
In a prospective clinical trial of 15 patients with SCD, Voskaridou et al. [18]
concluded that DFP decreased the serum ferritin levels significantly in 10/12 (83.3%)
subjects who completed the study. Treatment with deferiprone was not associated
with any major side effects in this study. Particularly, there was no evidence of
change in the liver function and no cytopenias, and only one patient had severe
gastrointestinal side effects.
Collins et al., 1994 [19] suggested as the mean daily urinary iron excretion
induced by DFP at 75mg/kg/d (0.48 ±0.23mg/kg) was equivalent to that induced by
DFO at 50 mg/kg/d (0.39±0.06 mg/kg).
Our findings from a long-term, multicenter, randomized clinical trial
9

demonstrate that DFP was not inferior to DFO in the treatment of iron overload in
patients with SCD.
Serum ferritin levels showed a linear decrease over time in both treatment
groups but the mean changes of serum ferritin levels over time did not differ between
the two treated groups. Moreover, applying the linear mixed-effects model (LMM) to
model serum ferritin in transfused versus non-transfused SCD enrolled patients, there
was not statistical significant difference in changing over the time of serum ferritin
levels between these two cohorts of patients (p= 0.389) (Tab. 4), although the basal
serum ferritin levels were higher in transfused compared with non-transfused group
(p=0.031) (Tab. 4). This last finding is similar to that reported by Brown et al., 2009
[10] who showed relationship between hepatic iron content and the transfusion
volume in 27 children with sickle cell anemia receiving chronic transfusion therapy
[10] .
The incidence of adverse events was similar between the two treated groups,
with treatment refusal and local reactions the main adverse events during DFO
treatment. Although the number of DFP treated patients was limited, the lack of
agranulocytosis, in DFP treated patients, during an overall period of observation of
192 person-years may be meaningful. An incidence of agranulocytosis ranging from
0.4 to 0. 6/100 person-years, as reported for patients with thalassemia major treated
with DFP [20,21] , might have led to at least one case of agranulocytosis in the
present trial. Previous trials on DFP in SCD patients did not suggest any effects on
liver function nor did they report agranulocytosis [18,22,23]. Nine patients enrolled
on DFP arm also received hydorxycarbamide for prevention of SCD crises. The lack
of agranulocytosis, during simultaneous treatment with DFP and hydroxycarbamide,
was previously reported, and the current study increases the number of patients
treated with DFP and hydroxycarbamide who did not develop agranulocytosis [24].
These findings suggest that the risk of agranulocytosis may be acceptable in SCD
patients treated with DFP.
Compliance was better with DFP (89%) in comparison with DFO treatment
(75%) as suggested by previous clinical trials in thalassemia major patients [25] .
Moreover, a similar low compliance was observed in several shorter-term SCD
clinical trials of hydroxyurea [26-28] and during DFX long-term safety and efficacy
study [13], suggesting that disease and social factors specific to SCD patient
populations may contribute substantially to low study completion rates [13].
The cost analysis did not show a statistical significant difference between the
two treatment groups (p= 0.43).
The results of survival curves, during the trial, even suggest that DFP does not
alter survival in comparison with DFO (Fig. 3). The causes of death in this study
were not related to iron overload or chelation therapy but were similar to those found
in the natural history of SCD [29] (Table 6). These findings are confirmed at the
follow-up after 5-years from the end of the trial (Tab. 7).
The limit of the study could be that serum ferritin levels in patients with SCD
have shown varying degrees of correlation with LIC, which is considered a more
direct measure of iron overload, especially in pediatrics patients [30,31].However, the
10

design of the study as randomized clinical trial, the effectiveness of treatment
evaluated at repeated measurement on the same patient over time of serum ferritin
levels and the inclusion in the trial of a large cohort of adult patients, may surely have
balance effect on this bias.
In conclusion, long-term iron chelation therapy with DFP was associated with
efficacy and safety similar to that of DFO. Therefore, in patients with SCD, DFP may
represent an effective long-term treatment option to accompany on-going transfusion
therapy, reducing the risk of developing complications of iron overload.
These findings, together with those reported for deferasirox[12,13], suggest
that oral chelation could be now a reasonable choice for the management of iron
overload in patients with SCD.
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The following institutions and investigators participated in the Multicenter
Randomized Clinical Trial of Deferiprone versus Deferoxamine in Sickle Cell
Disease: Clinical Centers (the numbers in parentheses are the numbers of patients
enrolled at each center) — Centro per la Talassemia e l’Anemia Falciforme, Azienda
Sanitaria Provinciale di Caltanissetta Vittorio Emanuele, Gela, Caltanissetta, Italy
(53): Alessandra Quota and Ketty Perrotta; Unità Operativa Complessa Ematologia II
, A.O.R. Villa Sofia – V. Cervello, Palermo, Italy (17): Antonino Giangreco and
Veronica Di Salvo; Centro per la Talassemia, Azienda Ospedaliera Universitaria
Policlinico Vittorio Emanuele – Santo Bambino, Catania, Italy (9): Turi Lombardo
and Gaetano Giuffrida; Unità Operativa Complessa di Pediatria, Ospedale Galliera,
Genova, Italy (6): Gianluca Forni; Unità Operativa Semplice Dipartimentale,
Azienda Ospedaliera S. Eugenio, Roma, Italy (3): Paolo Cianciulli; Unità Operativa
Complessa di Medicina Trasfusionale, Azienda Ospedaliera M. Paternò Arezzo,
Ragusa, Italy (3): Carmelo Fidone; Unità Operativa Semplice di Talassemia, Presidio
Ospedaliero S. Agata di Militello, Italy (2): Gaetano Roccamo; Unità Operativa
Complessa di Pediatria, Azienda Ospedaliera S. Antonio Abbate, Trapani, Italy (1):
Antonella Carollo
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Table 1. Baseline comparisons in the 60 patients included in the multi-center
randomized clinical trial comparing Deferiprone (DFP) versus Deferoxamine
(DFO) in Sickle-Cell-Disease.
Findings
N° pts
Females (%)
Age , years
Age at first transfusion, years
Mean age at DFO starting , years
Hgb, gr/dl*

DFP

DFO

p-value

30

30

---

46.67

53.33

0.7970

36.433±13,92

35.83±11.56

0.8565

6.95±8.03

7.81±11.94

0.7605

29.09±14.75

29.77±12.03

0.8593

9.59±1.68

9.26±1.27

0.4042

ALT, IU/L*
Total blood
transfusion,(ml/year)

37.51±22.24

45.97±41.67

0.3395

2055.05±1282.01

2797.15 ±2018.08

0.1901

Mean Hb pre-Tx, gr/dl

8.99±1.32

8.65±0.99

0.2955

1440.14±712.7

1726.03±694.01

0.1274

59.91±6.65

60.83±8.52

0.7731

Splenectomy (%)

45.4

70.6

0.1910

Cirrhosis (%)

13.3

11.5

1.000

Arrhythmia (%)

10.0

15.4

0.693

HCV-RNA positive (%)

18.52

12.00

0.705

Mean basal ferritin, ng/ml
Mean basal EF (%)
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Table 2. Means of serum ferritin levels (μg/l) during 5-year multi-center
randomized clinical trial comparing Deferiprone (DFP) versus Deferoxamine
(DFO) treatment in Sickle-Cell-Disease.
DFP

DFO

mean±sd (n)

mean±sd (n)

Baseline

1440.13±712.80 (29)

1726.03±694.01 (29)

1

1033.00±737.41 (19)

1522.64±954.98 (22)

2

1076.80±897.51 (15)

1100.05±798.61 (19)

3

580.10±581.56 (10)

1127.68±516.42 (16)

4

438.22±320.81 (9)

1078.26±356.31 (15)

5

695.00±597.74 (7)

1333.85±871.74 (14)

Years

Table 3. Linear Mixed Effect Model (LMM) to evaluate changes over time in
mean serum ferritin levels in Deferiprone versus Deferoxamine-treated group in
Sickle-Cell-Disease.
Coefficients

SE

95% CI*

1433.02

206.54

(1028.21; 1837.84)

pvalue
0.000

treat

-53.03

235.21

(-514.02; 407.95)

0.822

time

-184.85

66.52

(-315.23; -54.48)

0.005

treatXtime

112.61

81.69

(-47.52; 272.72)

0.168

0.11

0.05

(-0.01; 0.21)

0.055

Intercept

totTX
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Table 4. Linear Mixed Effect Model (LMM) to evaluate changes over time in
mean serum ferritin levels of transfused versus non-transfused patients with
Sickle-Cell-Disease enrolled in the multi-center randomized trial.

Intercept
TX
time
TXxtime

Coefficients

SE

95% CI*

p-value

1149,13
495,96
-179,81
78,11

200,88
229,71
82,54
90,61

(755.42; 1542.86)
(45.75; 946.17)
(-341.57; -18.03)
(-99.48; 255.70)

0.000
0,031
0,029
0,389

Table 5. Adverse events (AEs) in Sickle-Cell-Disease during the 5 years trial
comparing Deferiprone versus Deferoxamine.
DFO

DFP
Adverse events
Local reactions at the
infusion site
Fever or other
infections
Joint pain
Nausea
Vomit
Liver damage*
Treatment refusal
SCD crisis
Surgery
Mastitis

N

%

n

%

p-value

---

---

3

10.0

0.237

3

10.0

---

---

0.237

2
4
2
3
1
2
--2

6.7
13.3
6.7
10
3.3
6.7
--6.7

--------16
1
2
---

--------53.3
3.3
6.7
---

0.492
0.112
0.492
0.237
<0.001
1.000
0.492
0.492

*increase twice the normal value.
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Table 6. Causes of death, at 5-years, in patients included in the Sickle-CellDisease multi-center randomized clinical trial comparing Deferiprone versus
Deferoxamine.
Causes of death
Acute Chest Syndrome
Respiratory failure
Hepatic failure
Totals

n (%)
1 (16.7)
2(33.3)
3(50.0)
6

*Treatment

DFP
DFO
2DFO1DFP

*Treatment at randomization

Table 7. Causes of death, at 10-years, in patients included in the Sickle-CellDisease multi-center randomized clinical trial.
Causes of death

n (%)

*Treatment

Acute Chest Syndrome

1 (7,1)

DFO

Respiratory failure

4 (28,6)

3 DFO, 1 DFP

Hepatic failure

5 (35,9)

DFO

Marasmus senile

1 (7,1)

DFO

Averse events post vaccination in liver transplant

1 (7,1)

DFO

Cardio-circulatory arrest in pulmonary hypertension

1 (7,1)

DFO

Pulmonary embolism

1 (7,1)

DFO

Totals

14

*Treatment at death.
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Figure 1. Trial profile of Deferiprone versus Deferoxamine intervention during
the Sickle-Cell-Disease multi-center randomized clinical trial.
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Figure 2. Estimated profiles of the mean serum ferritin in the two treatmentgroups from the fitted Linear Mixed-Effects Model (LMM) during Sickle-CellDisease multi-center randomized clinical trial.
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Figure 3. Kaplan–Meier survival probability curves in the two treatment groups
during multi-center Sickle-Cell-Disease clinical trial (Deferiprone: continous
line; Deferoxamine: dashed line) (p=0.38)
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